Category - Developments

Theratechnologies (TSX:TH) presented positive 48-week efficacy and safety results at the IDWeek 2017 conference in San Diego for ibalizumab in patients infected with multidrug resistant HIV-1, who completed the 24-week...

Mallinckrodt (NYSE:MNK) has entered into a licensing agreement for development and commercialization of NeuroproteXeon’s pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and...

Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use...

Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively. Arcturus’ technology...

Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum...

The FDA has approved Arkis BioSciences’ CerebroFlo external ventricular drain (EVD) catheter that includes Interface Biologics’ Endexo technology. The CerebroFlo catheter has demonstrated a 99% reduction in thrombus...

American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong. After more than two years as CryoStem’s licensee in Hong Kong, HIT has licensed the patent rights to...

The HydRx Farms subsidiary of Scientus Pharma has received its Access to Cannabis for Medical Purposes Regulations (ACMPR) license from Health Canada. Scientus now is permitted to begin cultivating medicinal cannabis at...

Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for...

MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS...